A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions

被引:79
作者
Buttar, David [1 ]
Colclough, Nicola [1 ]
Gerhardt, Stefan [1 ]
MacFaul, Philip A. [1 ]
Phillips, Scott D. [2 ]
Plowright, Alleyn [3 ]
Whittamore, Paul [1 ]
Tam, Kin [1 ]
Maskos, Klaus [4 ]
Steinbacher, Stefan [4 ]
Steuber, Holger [4 ]
机构
[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
[2] Univ St Andrews, Dept Chem, St Andrews KY16 9ST, Fife, Scotland
[3] AstraZeneca, S-143183 Molndal, Sweden
[4] Proteros Biostruct, D-82152 Martinsried, Germany
关键词
Drug; Binding; Albumin; Fluorescence; Subdomain IB; Crystallography; PLASMA-PROTEIN BINDING; SITE-II; AFFINITY; INDOMETHACIN; SPECIFICITY; REFINEMENT; DIFLUNISAL; LOCATION; WARFARIN; PROBES;
D O I
10.1016/j.bmc.2010.08.052
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The displacement of probes that bind selectively to subdomains IIA or IIIA on human serum albumin (HSA) by competing compounds has been followed using fluorescence spectroscopy, and has therefore been used to assign a primary binding site for these compounds in the presence and absence of fatty acids. The crystal structures have also been solved for three compounds: a matched pair of carboxylic acids whose binding strength to HSA unexpectedly decreased as the lipophilicity increased; and a highly bound sulphonamide that appeared not to displace the probes in the displacement assay. The crystallography results support the findings from the fluorescence displacement assay. The results indicate that drug binding to subdomain IB might also be important location for certain compounds. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7486 / 7496
页数:11
相关论文
共 63 条
[1]  
Artali Roberto, 2005, Farmaco (Lausanne), V60, P485, DOI 10.1016/j.farmac.2005.04.010
[2]  
BENGTSSON M, 2006, Patent No. 2006051270
[3]  
BIRCH AM, 2006, Patent No. 2006082400
[4]   Binding interaction of indomethacin with human serum albumin [J].
Bogdan, M. ;
Pirnau, A. ;
Floare, C. ;
Bugeac, Carmen .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 47 (4-5) :981-984
[5]   EVIDENCE FOR ISOXICAM BINDING TO SITE-I AS A PRIMARY SITE AND TO SITE-II AS A SECONDARY SITE OF HUMAN-SERUM ALBUMIN [J].
BREE, F ;
NGUYEN, P ;
ALBENGRES, E ;
URIEN, S ;
RIANT, P ;
WELLING, PG ;
TILLEMENT, JP .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (05) :753-758
[6]   DISPLACEMENT OF TOLBUTAMIDE, GLIBENCLAMIDE AND CHLORPROPAMIDE FROM SERUM-ALBUMIN BY ANIONIC DRUGS [J].
BROWN, KF ;
CROOKS, MJ .
BIOCHEMICAL PHARMACOLOGY, 1976, 25 (10) :1175-1178
[7]  
Carter D. C., 2005, Patent No. [2005041895, WO2005041895-A2
[8]  
EP1684705-A2
[9]  
US2007043509-A1]
[10]  
CARTER DC, 2007, Patent No. 2007130950